Opinion|Videos|October 4, 2024
Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies
Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing early diagnosis and screening in patients with systemic lupus erythematosus.
Advertisement
Episodes in this series
- What are the goals of therapy for patients with lupus nephritis (LN)? What does urgency to treat mean in LN?
- What are the consequences of untreated LN or renal flares?
Objective: Examine strategies for early diagnosis/screening, updated treatment guidelines, and treatment and payer considerations to optimize lupus nephritis management and address patient access challenges.
- What strategies have you found effective in increasing the screening and early diagnosis of LN in patients with either diagnosed or suspected systemic lupus erythematosus (SLE)?
- Who are these patients who should be screened for LN?
How can payers support screening for LN in patients with SLE?
Advertisement
Related to this article
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD
4
International Panel Agrees on Framework for Tapering Psoriasis Biologics
5